Agenus (AGEN) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Agenus (AGEN) has outperformed Ocugen (OCGN) over the past year, gaining 80.8% versus a loss of 43.2%. Over five years, OCGN leads with a -88.5% price change compared with -92.8% for AGEN. Agenus is the larger company by market cap ($340.5 million vs $331.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | OCGN |
|---|---|---|
| Share price | $7.54 | $0.9774 |
| Market cap | $340.52M | $331.45M |
| 1-day change | -0.40% | -2.26% |
| YTD return | +140.13% | -25.93% |
| 1-year return | +80.82% | -43.18% |
| 5-year return | -92.77% | -88.45% |
| P/E ratio (TTM) | 2.98 | — |
| EPS (TTM) | $2.53 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $2.73 |
| 52-week low | $2.71 | $0.96 |
| Distance from 52-week high | -26.87% | -64.13% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.20% | +1145.14% |
| Average volume | 4.26M | 5.91M |
| Shares outstanding | 45.16M | 339.11M |
| Employees | 81 | 116 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed OCGN by 124.0 percentage points over the past year.
- The two companies sit in different sectors: Agenus in Healthcare and Ocugen in Health Care.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Healthcare · Biotechnology · 81 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
AGEN vs OCGN FAQ
Which is bigger, Agenus or Ocugen?
Agenus (AGEN) is larger, with a market capitalization of $340.52M compared with $331.45M for Ocugen (OCGN).
Which stock has performed better over the past year, AGEN or OCGN?
AGEN returned +80.82% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Ocugen in the same industry?
No. Agenus is in the Healthcare sector, while Ocugen is in Health Care.